TEST:

GlycoVision™

"InterVenn Biosciences...announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology. This groundbreaking research in early detection of CRC represents an advancement in early diagnosis through serum glycoproteome profiling. InterVenn’s GlycoVision™ platform leverages advanced liquid chromatography-mass spectrometry (LC-MS) combined with artificial intelligence (AI) and neural networks (NN) to interrogate a new layer of biology, enabling novel insights and discoveries."

"InterVenn Biosciences...presented new data at the 2023 Digestive Disease Week (DDW) annual conference, which was honored as a 'Poster of Distinction'. This data, generated by InterVenn’s novel, proprietary biomarker discovery platform, GlycoVision™, analyzed 575 retrospective samples and was able to achieve an overall sensitivity of 89% and specificity of 89% for predicting advanced adenoma (AA) and colorectal cancer (CRC). Separately, AA (N=32) was predicted with 87.5% sensitivity and CRC with 89.4% sensitivity. The sensitivity results of 87.5% for AA prediction is the highest that has been reported to date in the industry."

"InterVenn Biosciences...announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™, to detect advanced adenomas (AA) and colorectal cancer (CRC). The data will be presented as a 'Poster of Distinction' at the 2023 Digestive Disease Week Conference (DDW), being held May 6-9, in Chicago, IL....The abstract...highlights pre-cancer sensitivity via the assessment of circulating serum glycoproteins and has been selected as a 'Poster of Distinction' by the American Gastroenterology Association (AGA) Institute Council, among the top 10 percent of abstracts submitted."